Geode Capital Management
NKGN

Geode Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Geode Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-127,168
Closed -$83.3K – 4534
2024
Q4 		$83.3K Buy
127,168
+14,454
+13% +$5.89K ﹤0.01% 4143
2024
Q3 		$42.6K Buy
112,714
+44,275
+65% +$39.3K ﹤0.01% 4291
2024
Q2 		$86.9K Buy
68,439
+15,070
+28% +$21.1K ﹤0.01% 4172
2024
Q1 		$101K Buy
53,369
+7,519
+16% +$14.4K ﹤0.01% 4155
2023
Q4 		$126K Buy
+45,850
New +$148K ﹤0.01% 4105

Other funds holding NKGN

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Geode Capital Management's NKGN Position: Q1 2025 in Review

Geode Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 127,168 shares — an estimated $83.3K sold.

Geode Capital Management first reported a position in NKGN in Q4 2023 and held it in 5 quarters. The position peaked at $126K in Q4 2023. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

  • Geode Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 127,168 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $83.3K.
  • Geode Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2023 and held it in 5 quarters.
  • Geode Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $126K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.